BLCM - Bellicum Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
2,322
1,120
185
388
Cost of Revenue
-
-
-
-
Gross Profit
-
-
-
-
Operating Expenses
Research Development
70,799
71,152
65,663
51,263
Selling General and Administrative
31,554
25,434
21,909
17,505
Total Operating Expenses
102,353
96,586
87,572
68,768
Operating Income or Loss
-100,031
-95,466
-87,387
-68,380
Interest Expense
4,323
4,199
3,672
1,760
Total Other Income/Expenses Net
-
-10
-1,775
-10
Income Before Tax
-110,716
-98,036
-91,779
-69,241
Income Tax Expense
-
-
-
-
Income from Continuing Operations
-110,716
-98,036
-91,779
-69,241
Net Income
-110,716
-98,036
-91,779
-69,241
Net Income available to common shareholders
-110,716
-98,036
-91,779
-69,241
Reported EPS
Basic
-
-24.40
-28.90
-25.70
Diluted
-
-24.40
-28.90
-25.70
Weighted average shares outstanding
Basic
-
4,023
3,171
2,695
Diluted
-
4,023
3,171
2,695
EBITDA
-
-87,139
-84,543
-65,175